03.29.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene

Using cGMP grade reagents earlier makes for a seamless transition while maintaining quality and viability. Learn the key considerations to using high quality reagents ahead of time.

Delve deeper into the crucial elements of transparency that prospective clients should consider when partnering with a CDMO, including analytics, documentation, and more.

What are the key differences between traditional Limulus amebocyte lysate (LAL) assays and recombinant LAL assays for endotoxin testing? 

Without the resources needed to break through a competitive and volatile market, many nascent biotech companies and promising therapeutics can stall out well before reaching their commercial potential.

Many companies are turning to CDMOs to optimize biomanufacturing processes and address the growing list of complications on the path to commercialization.

Explore a study aimed at achieving clinically relevant cell numbers using the engineering of a GMP-compliant large-scale platform is essential.

Translating novel drug discoveries into clinical trials remains a complex endeavor. Learn how a CDMO with cutting-edge technologies can facilitate a smooth path from discovery to FIH studies.

See how bispecific pairing technology uses a close-to-nature design solution to deliver high accurate heavy-light chain pairing efficiencies and improved manufacturability.